SMART MONEY GROUP

[glenn1919]

IMPP..........CEI..........EDU..........QNGY..........NEWYY.........https://stockcharts.com/h-sc/ui?s=NEWYY&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=QNGY&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=EDU&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=CEI&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=IMPP&p=D&yr=0&mn=2&dy=12&id=p84071410134

[Let's Roll]

$GTCH GBT Technologies, Inc. “GBT” is a technology company focusing on chip design and software and is developing a portfolio of Intellectual Property that is targeted to have significant relevance in enabling the rollout of IoT (Internet of Things), global mesh networks, and for applications relating to artificial intelligence.

[Golden Cross]

$BLUE Heavy short volume yesterday... Lets watch the shorts fry the rest of the week - $10+ on the way!

[TheFinalCD]

1 Bitcoin (BTCUSD) 760% 114 BTCUSD 23657.71000000 -3009.38000000 -11.28% 54,604
2 Marketing Worldwide Corp. (MWWC) 327% 144 MWWC 0.0032 0.0006 23.08% 141,548,850
3 3Power Energy Group Inc. (PSPW) 286% 20 PSPW 0.0003 0.0 0.00% 0
4 iGen Networks Corp. (IGEN) 267% 32 IGEN 0.0035 -0.0004 -10.26% 1,825,986
5 Starfleet Innotech, Inc. (SFIO) 267% 24 SFIO 0.0165 -0.0025 -13.16% 5,880,769
6 The Hunt for the Next 10 Bagger 250% 20
7 Tilray, Inc (TLRY) 238% 19 TLRY 3.1715 -0.2085 -6.17% 19,281,935
8 ProShares Trust Ultra VIX Short Term Futures ETF (UVXY) 214% 30 UVXY 16.945 2.155 14.57% 79,319,245
9 Valiant Eagle Inc. (PSRU) 211% 40 PSRU 0.00085 -0.00055 -39.29% 91,946,048
10 Tesla, Inc. (TSLA) 208% 52 TSLA 657.74 -38.95 -5.59% 25,226,048
11 Ultrack Systems, Inc. (MJLB) 208% 50 MJLB 0.0066 -0.0044 -40.00% 3,113,167
12 Digital World Acquisition Corp (DWAC) 200% 28 DWAC 38.2303 -5.5597 -12.70% 1,239,701
13 Goff Corporation (GOFF) 196% 102 GOFF 0.482 -0.0949 -16.45% 1,136,669
14 FRONT PAGE STOCKS 192% 23
15 Asia Broadband, Inc. (AABB) 189% 87 AABB 0.061 -0.00335 -5.21% 13,425,878
16 Innerscope Hearing Technologies Inc. (INND) 188% 64 INND 0.0053 -0.0001 -1.85% 24,631,770
17 Sunshine Biopharma Inc. (SBFM) 177% 39 SBFM 1.17 -0.08 -6.40% 460,572
18 Grillit, Inc. (GRLT) 177% 23 GRLT 0.0006 -0.0001 -14.29% 5,771,500
19 Niocorp Developments Ltd. (NIOBF) 176% 44 NIOBF 0.68732 -0.01268 -1.81% 282,766
20 Social Life Network Inc. (WDLF) 167% 15 WDLF 0.0014 -0.0001 -6.67% 10,220,906
21 Redbox Entertainment Inc (RDBX) 164% 36 RDBX 15.05 1.85 14.02% 46,341,669
22 Movement Industries Corp. (MVNT) 163% 31 MVNT 0.0146 -0.0009 -5.81% 171,899
23 PCT Ltd. (PCTL) 161% 61 PCTL 0.01 0.0001 1.01% 878,218
24 Imperial Petroleum Inc (IMPP) 161% 158 IMPP 0.7845 -0.0975 -11.05% 149,629,001
25 Indoor Harvest Corp (INQD) 157% 11 INQD 0.006 -0.0004 -6.25% 1,505,776
26 Savvy Trades and Investments 154% 40
27 SPDR S&P 500 (SPY) 150% 72 SPY 379.52 -10.28 -2.64% 83,352,534
28 Trans Global Group Inc (TGGI) 146% 35 TGGI 0.0104 -0.0002 -1.89% 18,650,234
29 Innovation Pharmaceuticals Inc. (IPIX) 145% 16 IPIX 0.024 -0.0015 -5.88% 644,451
30 HUMBL Inc. (HMBL) 144% 13 HMBL 0.0894 -0.00665 -6.92% 3,465,482
31 Nutranomics, Inc (NNRX) 144% 23 NNRX 0.00025 0.0 0.00% 94,857,654
32 Solar Integrated Roofing Corp. (SIRC) 141% 55 SIRC 0.125 -0.0381 -23.36% 6,260,444
33 Regen BioPharma Inc (RGBP) 140% 35 RGBP 0.00395 -0.00025 -5.95% 14,654,030
34 Revive Therapeutics Ltd (RVVTF) 131% 17 RVVTF 0.33065 -0.00935 -2.75% 548,340
35 VirExit Technologies Inc. (VXIT) 131% 38 VXIT 0.0024 -0.0001 -4.00% 3,778,377
36 Nitches, Inc. (NICH) 129% 49 NICH 0.04 -0.003 -6.98% 519,332
37 Phoenix Rising Cos. (PRCX) 126% 29 PRCX 0.00305 -0.00055 -15.28% 12,940,932
38 Nightfood Holdings, Inc. (NGTF) 124% 26 NGTF 0.185 -0.015 -7.50% 144,043
39 AMC Entertainment Holdings Inc (AMC) 122% 122 AMC 11.465 -0.965 -7.76% 20,921,965
40 Mr. Cooper Group, Inc. (COOP) 119% 31 COOP 40.47 -1.37 -3.27% 528,315
41 Anavex Life Sciences Corp (AVXL) 117% 75 AVXL 7.625 -0.475 -5.86% 489,936
42 Whale Team 114% 8
43 SMART MONEY GROUP 113% 9
44 Shiba Inu Token (SHIBUSD) 113% 70 SHIBUSD 0.00000815 -0.00000045 -5.23% 56,131,538,384
45 IIOT-OXYS Inc. (ITOX) 111% 10 ITOX 0.0106 -0.0012 -10.17% 969,151
46 HPIL Holding (HPIL) 109% 25 HPIL 0.000735 0.000135 22.50% 71,930,801
47 Fannie Mae (FNMA) 106% 89 FNMA 0.56 -0.055 -8.94% 3,376,254
48 NSAV Holding, Inc. (NSAV) 104% 54 NSAV 0.0063 -0.00125 -16.56% 19,294,833
49 MOMO'S BREAKOUT BOARD 102% 135
50 Artificial Intelligence Technology Solutions Inc. (AITX) 100% 21 AITX 0.0144 -0.0011 -7.10% 17,261,847

https://investorshub.advfn.com/boards/breakoutboards.aspx

[l2 hunter]

++ EXBX 0175 last few cutrodian bottoms way R/M and $1 land potential imho. My next GOFF R/M speculation...Lazar has sold EXBX and GOFF Custodians. Check out EXBX before 10-Q next days/week? .


Ticker Buzz Cloud
24 Hours
12 Hours
6 Hours
3 Hours
1 Hour
AABB
AGYP
AITX
AMC
ANDI
APCX
BDCO
BIEL
BIG
BRLL
CYDY
DBMM
DEWM
DPLS
ECEZ
ENZC
ETEK
FTXP
GME
GOFF
GTCH
GTOR
GVSI
HHSE
HIRU
HPIL
HPNN
IMO
IMPP
INAR
INND
LWLG
MF
MJLB
MONI
MSFT
MULN
MYNZ
NECA
NEXT
NICH
NNRX
NSAV
NWBO
OPTI
PBHG
PCTL
PVSP
REAL
RGBP
RSHN
RUN
SYSX
VIZC

Ticker Buzz Cloud
24 Hours
12 Hours
6 Hours
3 Hours
1 Hour
(WTI)
AAPL
AGYP
AMC
APCX
APSI
BDCO
BDGR
BIEL
CLNV
CYDY
DBMM
ECEZ
ENZC
FUNN
GME
GNCP
GOFF
GTCH
GTOR
GVSI
HHSE
HIRU
HPIL
HPNN
HYMC
ICNM
ILUS
IMO
IMPP
ITOX
IVDN
MJLB
MONI
MSFT
MULN
MYNZ
NEWYY
NEXT
NICH
NSAV
NWBO
PBHG
PVSP
QEDN
QNTA
RBNW
RDBX
REAL
RGBP
RPTX
RUN
SNDL

[glenn1919]

YCBD..........OBLG...........NEWYY...........ORTX.........AMPE..........https://stockcharts.com/h-sc/ui?s=AMPE&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=ORTX&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=NEWYY&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=OBLG&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=YCBD&p=D&yr=0&mn=2&dy=12&id=p84071410134

[gp22]

:BRN @ $2.80s: Float 5.4M. EPS .21 last Q w/$65 Oil...Last one to go orbital


BRN to easy to pass up.

Link:
https://finance.yahoo.com/news/barnwell-industries-inc-reports-earnings-100000142.html

[LoveItInBishop]

FULC great price here. Loaded more. Fell Friday, overreaction

[Penny Whipped]

GEGI should be getting an update soon

$GEGI company gonna Announce her new Directions with the new CEO any day now. https://t.co/toVWLAn8hL
* And here is a little hint from the CEO profile😉"Big announcements to come"👀 https://t.co/SyenQUOzlc pic.twitter.com/Vis4sgBGq4

— 0x293 (@GODS__TRADE) June 13, 2022

[Soulman856]

TOP off running again. Low float china play. Up all last week and not stopping

[Let's Roll]

$PSVP ZAM’s focus is on providing the best possible infrastructure, expertise and support to ensure each cultivator’s success. ZAM also is charged with managing the implementation and adherence to all Artizen brand guidelines. With years of experience in consumer packaged goods marketing, grow facility management, and finance, ZAM’s team understands what is needed for a cultivator to be at the top of their game and have access to various resources when needed.

[TheFinalCD]

https://www.reddit.com/r/RDBX/comments/va2gq1/missing_the_real_issue/?utm_medium=android_app&utm_source=share

[BADALI]

$CBDD updated DD on June 12,2022
CBDD Some DD with PR, YouTube and Zoom sources and Coming updates :
- [x] Company Name and Ticker Change
- [x] More acquisitions
- [x] Company structure
- [x] More Revenue generating and profitable updates
- [x] MEDIA COVERAGE
- [x] Ceo of CBDD interview link : interview from earlier today at @Benzinga All Access event. It was excellent to share our growth plans with a wider investment audience.

- [x] CBD of Denver Subsidiary Mellow Signs Agreement with Australian CBD and Hemp Wellness Brand : 6.8.2022. https://www.newsfilecorp.com/release/126905/CBD-of-Denver-Subsidiary-Mellow-Signs-Agreement-with-Australian-CBD-and-Hemp-Wellness-Brand?k=Cbdd
- [x] FORBES June5,2022 Switzerland To Launch Adult-Use Cannabis Sale Trial Program This Summer
- [x] https://www.forbes.com/sites/dariosabaghi/2022/05/05/switzerland-to-launch-adult-use-cannabis-sale-trial-program-this-summer/?sh=67d426135230
- [x] MICROCAPDAILY: June5, 2022. CBD of Denver (OTCMKTS: CBDD) Investors Looking for Big Week Ahead as European CBD Innovator Marks Expansion into German Medical Cannabis Market https://microcapdaily.com/cbd-of-denver-otcmkts-cbdd-european-cbd-innovator-marks-expansion-into-german-medical-cannabis-market/
- [x] ABOUT CBDD: CBD of Denver, Inc. (OTC Pink: CBDD) a full-line Distributor of CBD and Cannabis flower and a producer of a full line of CBD oil and unique products sold in Switzerland and throughout Europe. CBD of Denver, Inc. is focused on using equity to acquire profitable assets at attractive valuations to create value for all our shareholders and is driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis. Through our Rockflowr brands we have built a very strong European customer base by focusing on top quality products and meaningful customer relationships.
- [x] Website Link:
- [x] CBDD https://www.cbdofdenver.com
- [x] ROCKFLOWR https://www.rockflowr.com/

INSTAGRAM LINKS:
- [x] CBD OF DENVER INC : https://instagram.com/cbdofdenver_inc?igshid=YmMyMTA2M2Y=
- [x] ROCKFLOWER OFFICIAL: https://instagram.com/rockflowr?igshid=YmMyMTA2M2Y=
- [x] ROCKFLOWR : https://instagram.com/rockflowr?igshid=YmMyMTA2M2Y=
- [x] ROCKFLOWR RETAIL : https://instagram.com/rockflowr_retail?igshid=YmMyMTA2M2Y=
- [x] SWISSGREENGROW: https://instagram.com/swissgreengrow?igshid=YmMyMTA2M2Y=
- [x] SWISSCBDTRADING: https://instagram.com/swissgreengrow?igshid=YmMyMTA2M2Y=
- [x] ABOUT MELLOW: Mellow group operates as a multi-brand eCommerce Marketplace, a full-service digital & performance marketing agency, as well as a market expansion service into the Asian markets. Recently acquired by CBD of Denver, mellow is playing a key role in expanding the CBDD business revenue streams, as well as diversifying the brand portfolio, as part of a commercial roll-up strategy.
- [x] Mellow website Links:
www.mellow.store
www.mellowasia.store
INSTAGRAM LINK:
https://instagram.com/mellow_talk?igshid=YmMyMTA2M2Y=
- [x] ABOUT OTO
OTO is a luxury lifestyle brand spanning CBD beverages, beauty, spa and wellbeing. OTO is a leader in the global premium CBD space with listings in luxury retailers, such as Harrods, Liberty and Selfridges, as well as five-star hotel groups, including Mandarin Oriental, Marriot, Ennismore and Langham. In using only pure CBD isolate, OTO is also able to easily, confidently and transparently navigate Hong Kong laws in relation to CBD and the zero THC policies that are enforced.

1. CBD of Denver Subsidiary Mellow Signs Agreement with Australian CBD and Hemp Wellness Brand https://www.newsfilecorp.com/release/126905/CBD-of-Denver-Subsidiary-Mellow-Signs-Agreement-with-Australian-CBD-and-Hemp-Wellness-Brand?k=Cbdd
2. CBD of Denver Signs Licensing Agreement with UK Luxury CBD Brand OTO https://www.newsfilecorp.com/release/125408/CBD-of-Denver-Signs-Licensing-Agreement-with-UK-Luxury-CBD-Brand-OTO?k=Cbdd
3. CBD of Denver Announces First Quarter 2022 Financial Results https://www.newsfilecorp.com/release/124486/CBD-of-Denver-Announces-First-Quarter-2022-Financial-Results?k=Cbdd
4. CBD of Denver Expands into Europe's Largest Cannabis Market https://www.newsfilecorp.com/release/122571/CBD-of-Denver-Expands-into-Europes-Largest-Cannabis-Market?
5. CBD of Denver Reports Record $23.5 Million Revenue in 2021. Company filed audited financial statements for fiscal year 2021 on April 15, 2022 https://www.newsfilecorp.com/release/121178/CBD-of-Denver-Reports-Record-23.5-Million-Revenue-in-2021?k=Cbdd
6. CBD of Denver Signs Agreement to Acquire CBD E-Commerce Distribution Platform and Technology Company Mellow https://www.newsfilecorp.com/release/119308/CBD-of-Denver-Signs-Agreement-to-Acquire-CBD-ECommerce-Distribution-Platform-and-Technology-Company-Mellow?k=Cbdd

6. CBDD Appoints Finance Veteran Paul Gurney as New CEO https://www.newsfilecorp.com/release/115969/CBD-of-Denver-Appoints-Finance-Veteran-as-New-CEO?k=Cbdd

7. # CBDD : 1st Quarter 2022 Earnings Zoom Call with CEO Paul Gurney and RedChip
https://redchip.zoom.us/rec/play/3TsgylninM1h4eaNQxkzoyhoTjFNumotLwCiIrhsNVCTYXfkS_iKCZ8QD6ks_E10062IpHvWEV360dZf.WwUM0FcmzSR7tdq1

8. Recent interview clip from @BzCannabis conference 2022 in Miami with CEO Paul Gurney of CBD of Denver #CBDD

9. CEO of CBDD Paul Gurney talk with Red Chip on Zoom

https://us06web.zoom.us/rec/play/MhT6o71yPvxvh5vke8igmor3qCsRZLxRYHmT1c6b-a1hHr1w5uRdd6oQ67sqV508Q6pAxmZ0wrQHJPSQ.vg_-xK6B6g1bXIDQ?continueMode=true&_x_zm_rtaid=vh3NZ4uRT6CsSIbzQrxYKQ.1646943089330.f5967b639e7c5da5551607fee5043c66&_x_zm_rhtaid=428

[Alexulf]

Authorization of Alcohol License

https://investor.plantx.com/news-events/

[Alexulf]

AITX Robotics Gained Momentum Again - Continuation Coming Week?

https://www.barchart.com/stocks/quotes/AITX/overview

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjfl4HlwKf4AhVQrosKHeYcA_sQFnoECCQQAQ&url=https%3A%2F%2Faitx.ai%2F&usg=AOvVaw2_yQ2Lhma_8Shv11jpeY8f

[Golden Cross]

$BLUE---FDA Approval almost certain here $$$$

[Golden Cross]

$BLUE FDA advisory committee unanimous in support of Bluebird Bio’s two gene therapies
It’s a much-needed win for the struggling Cambridge biotech, but doesn’t guarantee approval.
By Ryan Cross Globe Staff,Updated June 10, 2022, 2 hours ago

A scientist at work in a Bluebird Bio lab.PAT GREENHOUSE/GLOBE STAFF
Bluebird Bio scored a much-needed win on Friday when a committee of independent scientists and doctors voted unanimously in favor of recommending Food and Drug Administration approval of the firm’s two gene therapies. The panel said that the treatments’ benefits outweighed any potential risks, including blood cancers that a few trial participants developed.

Even Bluebird was taken aback by the overwhelming support. “I was hopeful we would have positive outcomes, but this was even more than I expected,” chief executive Andrew Obenshain said. “This was an enormously gratifying moment for us.”

Trading in the struggling Cambridge biotech’s stock was halted Thursday and Friday during the two-day FDA advisory panel’s meeting. Before the meeting, the stock was down 98 percent over three years following a spate of troubles, including concerns about the safety of Bluebird’s therapies and fierce debates over their costs. In April, the company said it would lay off 30 percent of its staff to maintain enough cash to last into the first half of 2023.

But the tide could be turning for the company. Over two days, the FDA’s Cell, Tissue, and Gene Therapies Advisory Committee heard from Bluebird executives, FDA scientists, and patient advocates about the safety and effectiveness of Bluebird’s therapies: beti-cel for the rare blood disease beta-thalassemia and eli-cel for a lethal neurodegenerative disease — cerebral adrenoleukodystrophy — that afflicts young children.

While the seal of approval from the committee is welcome news for Bluebird, it is not the final word for the two therapies. The FDA must rule on the therapies, and its decision is due by mid-August for beti-cel and by mid-September for eli-cel. Even then, approval does not guarantee commercial success for the therapies, which could cost millions of dollars and meet resistance from insurers.

Both therapies are based on an engineered virus called a lentiviral vector, which is used to transfer a gene into a patient’s blood stem cells. The technique promises to give patients a permanent working copy of a gene to supplant their broken or missing copy. But depending on where that new gene lands in an individual’s DNA, it can crank up the activity of other genes linked to cancer.

Dr. Wilson W. Bryan, director of the FDA’s Office of Tissues and Advanced Therapies, opened the meeting by stating the agency’s concerns about the risk of blood cancers that arose in some patients receiving Bluebird’s therapies. Although he acknowledged a “tremendous” need for cerebral adrenoleukodystrophy therapies, “patients should not be subjected to products that are ineffective or have an unfavorable risk-benefit profile,” he said.

On Thursday, Bluebird presented data indicating that 92 percent of children with cerebral adrenoleukodystrophy were still alive two years after eli-cel treatment compared to 57 percent of those without treatment. Bluebird also compared eli-cel to standard stem cell transplants sometimes used to treat the disease. The outcomes for children on eli-cel was essentially identical to children who got stem cell transplants from genetically matched donors — such as a sibling.

But children were got eli-cel fared far better than those who got transplants from a mismatched donor; only 43 percent of them survived over two years.

Those striking results were marred by blood cancers that arose in three out of 67 patients who received eli-cel. Dr. Laura Demopoulos, Bluebird’s vice president of pharmacovigilance, said the company plans to monitor signs of cancer every six months if the therapy is approved, which should be feasible since few people are expected to receive it. “We anticipate approximately 10 patients per year will be treated given the rarity of the disease,” she said.

Dr. Christine Duncan, a physician at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center said that she was “very pleased” with the committee’s vote of confidence, especially since it was not guaranteed. “Our young patients and their families stand to benefit tremendously from eli-cel,” she said in an e-mail.

On Friday, Bluebird presented data from its beta-thalassemia study in patients who require regular blood transfusions to maintain healthy levels of oxygen-carrying blood cells. Bluebird’s gene therapy, beti-cel, provides those patients with a gene that restores their ability to make healthy blood cells. About 90 percent of patients who received the treatment were able to remain transfusion-free, some for as long as seven years.

The company said that there were no cases of cancer linked to beti-cel which uses a slightly different lentiviral vector than eli-cel.

“The therapy is effective and the benefits outweigh the risks,” said Dr. Stuart Orkin, a scientist at the Harvard Stem Cell Institute and a physician at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. “I think things are being carefully done, and patients should feel gratified that something will come along for them.”

The fact that clinicians on the advisory committee said the benefits of eli-cel outweighed its risks was encouraging to other biotech companies developing lentiviral gene therapies, including Worcester-based Mustang Bio. “It is definitely a bellwether, because the whole field of gene and cell therapy is still very young,” said Knut Niss, chief technology officer of the firm.

But even if the FDA ultimately approves eli-cel, the ultimate question is how the market responds to the treatment, Niss added. “To me that is the bigger bellwether.”

Another company, Boston- and London-based Orchard Therapeutics, currently sells a lentiviral gene therapy in Europe. That therapy, Libmeldy, carries a price tag of about $3.8 million, and the company has only administered it to three patients since its approval. Orchard plans to submit Libmeldy to the FDA later this year or early next.

But if Bluebird’s beti-cel or eli-cel gets FDA approval in the coming months, those therapies will be the first lentiviral gene therapies for a rare disease in the United States. “That will be an important moment,” said Dr. Bobby Gaspar, chief executive of Orchard. “And I hope what happens with Bluebird is just the start.”

[Golden Cross]

$BLUE Could be a millionaire-maker
https://www.fool.com/investing/2022/06/10/an-fda-approval-could-send-this-stock-soaring-by-a/

[Soulman856]

TOP —-is the ticker for next week. Getting accumulated now, looks like a pump coming soon. Has gone up steady all week

[glenn1919]

GLDG...........NDRA...........NEWYY..........https://pennystocks.com/ticker/?symbol=NEWYY

https://pennystocks.com/ticker/?symbol=NDRA

https://pennystocks.com/ticker/?symbol=GLDG

[ListenToMe]

SELL EVERYTHING & BUY SHROOM STOCKS!$$$$
That is what I'm doing for myself!!!$$$

Let's see if I made a good choice!...???

[TheGreenReaper]

BBIG$$$$$
LOADING ZONE

[glenn1919]

PBTS.........QNGY............YSG..........NEWYY.........https://pennystocks.com/ticker/?symbol=NEWYY

https://pennystocks.com/ticker/?symbol=PBTS

https://pennystocks.com/ticker/?symbol=QNGY

https://pennystocks.com/ticker/?symbol=YSG

[Thehustle]

ITNS 0016 SHELL RISK BADGE REMOVED!!! DEAL WITH CVS IN WORKS! Boooooom COPPER RUNNER!

$ITNS

Got their shell risk badge removed today.. 👀

Looks like they are going into some business activity
Could be an acquisition or a reverse merger 🤝

Well, in both cases Im loading the hell out of it!
(DD thread bellow 👇) https://t.co/sVpKb4hRiM pic.twitter.com/QR7aAgLD9D

— L𝗶KO (@Likko_G) June 6, 2022

“Company has entered into an agreement with CVS Pharmacy to participate in their Test & Learn Program for our flagship product, Emesyl®.”

https://www.otcmarkets.com/otcapi/company/financial-report/326034/content

[Let's Roll]

$GTCH Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - June 1, 2022) - Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye, featuring an exclusive interview with the CTO of technology company, GBT Technologies Inc. (OTC Pink: GTCH).

Watch the video on YouTube:

Listen to today's podcast:
https://www.investorideas.com/Audio/Podcasts/2022/053122-AI-Eye-GBT.mp3

https://www.barrons.com/articles/ai-eye-podcast-gbt-cto-discusses-hippocrates-qterm-and-ai-in-healthcare-01654085269?mod=md_stockoverview_news

[Soulman856]

TOP keeps going up! Getting more now

[Robertscott]

$GTCH Updated Chart
https://www.stockscores.com/chart.asp?TickerSymbol=gtch&TimeRange=1300&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=830&ChartHeight=500&LogScale=None&Band=None&avgType1=SMA&movAvg1=&avgType2=SMA&movAvg2=&Indicator1=RSI&Indicator2=AccDist&Indicator3=MACD&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

[Robertscott]

$GTCH Updated Trader's Cheat Sheet https://www.barchart.com/stocks/quotes/GTCH/cheat-sheet

[glenn1919]

NEWYY...........PBTS............MOHO.........CPHI..................https://stockcharts.com/h-sc/ui?s=CPHI&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=PBTS&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=NEWYY&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=MOHO&p=D&yr=0&mn=2&dy=12&id=p84071410134

[~MulaGreen~]

^$PBTS MoolllahGreen after baghodling so Long,Next is BRQS eom

[Soulman856]

TOP lower floater. Has been going up slowly all week. Someone accumulating. Might be pre pump right now

[BLULLISH]

HOLLYWOOD_MOVIES_NFT_https://finance.yahoo.com/news/valiant-eagle-inc-otc-psru-130000851.html

AMERICAN_BASKETBALL_ASSOCIATION_https://www.marketwatch.com/press-release/xavier-media-group-a-valiant-eagle-inc-otcpsru-subsidiary-inks-a-colossal-television-deal-with-american-basketball-association-2021-08-31?mod=mw_quote_news_seemore

UPDATE ALERT__ https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169079891

[stock1ace1]

Xpon 2 mill float

[glenn1919]

PBTS..........KTRA.........CPOP..........IMPP..........NEWYY...........https://stockcharts.com/h-sc/ui?s=NEWYY&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=IMPP&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=CPOP&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=KTRA&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=PBTS&p=D&yr=0&mn=2&dy=12&id=p84071410134

[stock1ace1]

Xpon $2.78 ** 2 mill float news 8k

[Let's Roll]

$PVSP The two companies will also explore a potential merger in the future, depending on market conditions and regulatory approvals, that would significantly increase market share in North America. A potential merger would be dependent on due diligence by both parties, Freedom Cannabis pursuing a public offering in Canada, and legalization of cannabis at the federal level in the US.

“We are very pleased to have formed a working relationship with Artizen,” explained JohnFrank Potestio. “Artizen shares the same values as Freedom Cannabis and is dedicated to becoming one of the leading brands in North America. This provides a significant opportunity for Freedom to access the US market while continuing to build its brand in Canada.”

[~MulaGreen~]

HTCR No.#1 in Japan: HeartCore Authorizes $3.5 Million Share Repurchase Program
https://www.globenewswire.com/news-release/2022/06/08/2458750/0/en/HeartCore-Authorizes-3-5-Million-Share-Repurchase-Program.html
https://finviz.com/quote.ashx?t=HTCR

https://www.heartcore.co.jp/

[TheFinalCD]

great call my friend https://ih.advfn.com/stock-market/NASDAQ/imperial-petroleum-IMPP/stock-price

[Pyramid2]

I just love ugly.

[Pyramid2]

$HUSA, through $7's and wow, $IMPP another $WOW.

[benhor]

$SYSX It's gonna be a NASDAQ Stock

[ProfitScout]

$CURR News: CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children's Hospital Medical Center (CCHMC) Using CURE's Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Transplantation (HSCT)

Click here:
https://www.globenewswire.com/news-release/2022/05/12/2442338/0/en/CURE-Pharmaceutical-Announces-Positive-Findings-from-Study-at-Cincinnati-Children-s-Hospital-Medical-Center-CCHMC-Using-CURE-s-Proprietary-Oral-Thin-Film-OTF-High-Single-Dose-Vitam.html

About CURE Pharmaceutical

CURE Pharmaceutical is the pioneering developer of CUREform(TM), a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. Among CURE's key products is its oral thin film, 40,000 IU dose Vitamin D, (Branded Nutri-Strips(TM) in the Retail Market). Each strip is hermetically sealed in airtight, grab-and-go packaging to eliminate chemical and structural breakdown and provide superior potency. Nutri-Strips(TM) are available online at https://www.nutristripnow.com/immund3

As a vertically integrated company, CURE's 25,000 square foot, FDA-registered, NSF and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

[glenn1919]

YSG............SOS.............TRVN............WTRH...........NEWYY..........https://stockcharts.com/h-sc/ui?s=NEWYY&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=WTRH&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=TRVN&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=SOS&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=YSG&p=D&yr=0&mn=2&dy=12&id=p84071410134

[gp22]

BRN @ $2.90s: Total market cap $29M..EPS. 21 when oil was $65 in Q1...Insane Q2 #s on tap..Ripper developing.

[glenn1919]

DRRX...........AMPE............WTRH.............NEWYY............https://stockcharts.com/h-sc/ui?s=NEWYY&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=AMPE&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=DRRX&p=D&yr=0&mn=2&dy=12&id=p84071410134

https://stockcharts.com/h-sc/ui?s=WTRH&p=D&yr=0&mn=2&dy=12&id=p84071410134

[Alexulf]

Authorization of Alcohol License The Difference?

https://investor.plantx.com/press_release/pla...ice-beach/

[Slimer84]

$AGYP Company has recently executed documents to retire 2,480,000 unrestricted common shares of AGYP stock. This retirement represents a 4% reduction in the authorized shares of the company.

Confirmation of this retirement will reflect on the OTCMarkets' “Security Details" tab and specifically the “Outstanding Shares”, “Unrestricted” and “Held at DTC” sections will be reduced by 2,480,000. The company’s Transfer Agent VStock will facilitate the retirement of the shares. The company will continue to update shareholders regarding share structure changes.

https://www.otcmarkets.com/stock/AGYP/news/Allied-Energy-Execute-Documents-To-Retire-2480000-Common-Shares-From-Public-Float?id=355772

[Robertscott]

$PVSP Located in beautiful Port Townsend, on the northern end of the Olympic Peninsula, this gorgeous light deprivation greenhouse garden is producing beautiful flower and is home to some of the more exotic genetics in the Artizen brand. At 39,000 square feet it is the second largest of all of the gardens growing Artizen branded flower.

[~MulaGreen~]

HLBZ Strong Buy...pps @ the Bottom from 52wk hi of $41.88
https://finviz.com/quote.ashx?t=HLBZ&ty=c&ta=1&p=d

[Let's Roll]

$PVSP The two companies will also explore a potential merger in the future, depending on market conditions and regulatory approvals, that would significantly increase market share in North America. A potential merger would be dependent on due diligence by both parties, Freedom Cannabis pursuing a public offering in Canada, and legalization of cannabis at the federal level in the US.

“We are very pleased to have formed a working relationship with Artizen,” explained JohnFrank Potestio. “Artizen shares the same values as Freedom Cannabis and is dedicated to becoming one of the leading brands in North America. This provides a significant opportunity for Freedom to access the US market while continuing to build its brand in Canada.”